Multiple Sclerosis
Conference Coverage
MS relapse rates similar between anti-CD20 mAbs and switching to fumarates
Although overall health care encounters did not statistically differ between patients who switched from anti-CD20 monoclonal antibodies to...
Conference Coverage
Shingles infection rates higher in patients with MS
Even among patients with MS who had no baseline immunosuppression from therapy, rates of herpes zoster infection were significantly higher than...
Conference Coverage
Ozanimod for relapsing MS shows long-term safety, efficacy with age differences
Urinary tract infections and other treatment-emergent adverse events increased with age, but respiratory infections were more common among...
Conference Coverage
Multiple changes in NMOSD treatment for nonmedical reasons tied to poorer outcomes
“Our data highlight that aspects outside of therapeutic efficacy may be remarkably meaningful in the effective suppression of disease advancement...
Conference Coverage
Racial, ethnic disparities persist in access to MS care
Hispanic patients were significantly more likely to consistently report lower access to MS-specific care and feeling less heard by their health...
Conference Coverage
Long-term freedom from NMOSD relapse with satralizumab
At week 240 (4.6 years), 72% of satralizumab-treated patients were relapse-free, with 91% free from severe relapse.
Conference Coverage
Mindfulness-based stress reduction program benefits MS patients
Two separate programs showed significant improvements in participants’ stress, depressive and anxiety symptoms, self-awareness, and self-efficacy...
Literature Review
Stem cell transplants are more effective than some MS therapies
The results of the new study are “encouraging,” but plenty of unanswered questions remain.
Conference Coverage
Teriflunomide delays MS symptoms in radiologically isolated syndrome
The data support the theory that treatment should begin early in patients with a high likelihood of developing symptomatic MS on the basis of...
Conference Coverage
High-dose vitamin D and MS relapse: New phase 3 data
The study found no benefit, but was the exclusion criteria to blame?